Next Article in Journal
A Roadmap of In Vitro Models in Osteoarthritis: A Focus on Their Biological Relevance in Regenerative Medicine
Next Article in Special Issue
The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
Previous Article in Journal
Long-Acting Reversible Contraception: Placement, Continuation, and Removal Rates at an Inner-City Academic Medical Center Clinic
Previous Article in Special Issue
Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients
Review

Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies

1
Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain
2
Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
3
Department of Haematology, University Hospital of Valladolid, 47003 Valladolid, Spain
4
Department of Medicine, University of Salamanca, 37007 Salamanca, Spain
5
Department of Internal Medicine, University Hospital Rio Hortega, 47012 Valladolid, Spain
6
Department of Medicine, University of Valladolid, 45005 Valladolid, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Helen A. Papadaki
J. Clin. Med. 2021, 10(9), 1919; https://doi.org/10.3390/jcm10091919
Received: 28 March 2021 / Revised: 17 April 2021 / Accepted: 23 April 2021 / Published: 28 April 2021
(This article belongs to the Special Issue Myeloid-Derived Suppressor Cells (MDSCs) in Haematology)
Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice. View Full-Text
Keywords: myeloid-derived suppressor cells (MDSCs); immune checkpoint inhibitors (ICIs); haematological malignancies; immune resistance myeloid-derived suppressor cells (MDSCs); immune checkpoint inhibitors (ICIs); haematological malignancies; immune resistance
Show Figures

Figure 1

MDPI and ACS Style

Olivares-Hernández, A.; Figuero-Pérez, L.; Terán-Brage, E.; López-Gutiérrez, Á.; Velasco, Á.T.; Sarmiento, R.G.; Cruz-Hernández, J.J.; Miramontes-González, J.P. Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. J. Clin. Med. 2021, 10, 1919. https://doi.org/10.3390/jcm10091919

AMA Style

Olivares-Hernández A, Figuero-Pérez L, Terán-Brage E, López-Gutiérrez Á, Velasco ÁT, Sarmiento RG, Cruz-Hernández JJ, Miramontes-González JP. Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. Journal of Clinical Medicine. 2021; 10(9):1919. https://doi.org/10.3390/jcm10091919

Chicago/Turabian Style

Olivares-Hernández, Alejandro, Luis Figuero-Pérez, Eduardo Terán-Brage, Álvaro López-Gutiérrez, Álvaro T. Velasco, Rogelio G. Sarmiento, Juan J. Cruz-Hernández, and José P. Miramontes-González. 2021. "Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies" Journal of Clinical Medicine 10, no. 9: 1919. https://doi.org/10.3390/jcm10091919

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop